In thyroid cancer cells, OL and Ac-OL inhibited the phosphorylation of ERK and Akt proteins, showing potential as therapeutic agents for thyroid cancers with genetic alterations in the MAPK and Akt pathways. The gene discussed is AKT1; the disease is thyroid gland carcinoma.